Litigation Details for Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc (N.D. Tex. 2016)

Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc (N.D. Tex. 2016)

Docket		Date Filed	2016-07-29
Court	District Court, N.D. Texas	Date Terminated	2017-05-24
Cause	35:271 Patent Infringement	Assigned To	James E. Kinkeade
Jury Demand	Plaintiff	Referred To
Parties	TARO PHARMACEUTICAL INDUSTRIES LTD
Patents	8,445,543; 8,785,420; 8,809,305
Attorneys	Stephanie Rene Barnes
Firms	Law Office of Daniel Denton
Link to Docket	External link to docket

Details for Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc (N.D. Tex. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-07-29				External link to document
2016-07-29	32		infringement of U.S. Patent Nos. 8,445,543 (the “’543 Patent”), 8,785,420 (the “’420 Patent”), and 8,809,305…8,809,305 (the “’305 Patent”), collectively “the patents-in-suit.” Generally, the patents-in-suit relate to…asserted patents, which are purportedly owned by Galderma R&D. Without an exclusive patent license… patents-in-suit, and any foreign counterparts or priority applications to the patents-in- … patents-in-suit; • Plaintiffs’ theories regarding alleged infringement of the patents-in-suit	External link to document

Galderma Laboratories v. Taro Pharmaceuticals: Litigation Summary, Patent Scope, and Generic Entry Risk

Last updated: August 2, 2026

Galderma Laboratories LP sued Taro Pharmaceuticals USA Inc. in the U.S. District Court for the District of New Jersey after Taro filed an abbreviated new drug application for a generic version of Soolantra, Galderma's ivermectin 1% cream. The case, No. 3:16-cv-02207, was a Hatch-Waxman patent action triggered by Taro's Paragraph IV certification. The dispute centered on Galderma's patent protection for topical ivermectin compositions and their use in treating rosacea.

The case did not produce a reported merits decision invalidating Galderma's patent estate. Its commercial significance was the timing and terms of generic entry, which depended on the asserted patent, any later Orange Book-listed patents, and the parties' resolution of the ANDA litigation.

What drug and ANDA were involved in Galderma v. Taro?

The litigation involved Soolantra Cream, 1%, whose active ingredient is ivermectin. Galderma markets Soolantra for the topical treatment of inflammatory lesions associated with rosacea.

Item	Detail
Brand drug	Soolantra Cream, 1%
Active ingredient	Ivermectin
Dosage form	Topical cream
Reference sponsor	Galderma Laboratories LP
Generic applicant	Taro Pharmaceuticals USA Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of New Jersey
Civil action	No. 3:16-cv-02207
Filing year	2016
Dispute type	Paragraph IV patent litigation

Taro's ANDA sought approval to market a generic ivermectin 1% cream before the expiration of Galderma's listed patent rights. Galderma responded under 21 U.S.C. § 355(j)(5)(B)(iii), which created an automatic FDA approval stay of up to 30 months unless the litigation was resolved earlier or the court entered a decision affecting the stay.

What patents protected Soolantra in the Galderma-Taro litigation?

The principal patent associated with the Soolantra litigation was U.S. Patent No. 9,066,856, covering ivermectin compositions and methods of use. The patent was assigned to Galderma Laboratories or an affiliated Galderma entity and was listed in the FDA Orange Book for Soolantra.

Patent	Subject matter	Relevance
U.S. Patent No. 9,066,856	Ivermectin compositions and therapeutic use	Core formulation and method-of-use protection for Soolantra
Related Soolantra patents	Formulation, use, and product protection	Could affect approval and launch timing depending on listing and asserted claims

The asserted rights were not limited to ivermectin as a chemical compound. Ivermectin had long been known as an antiparasitic agent. Galderma's commercial protection instead focused on the topical formulation and the use of ivermectin for rosacea-related dermatological conditions.

This distinction matters. A generic applicant can avoid a composition claim by changing excipients or manufacturing conditions, but it must still address method-of-use claims if the proposed label includes the patented indication. ANDA applicants commonly use Section viii statements to omit protected indications where the FDA labeling permits a non-infringing carve-out.

What was the legal basis for Galderma's complaint?

Galderma's complaint alleged that Taro's Paragraph IV certification constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2). The alleged infringement arose from Taro's submission of an ANDA seeking approval for a product that Galderma contended would infringe the Soolantra patent upon manufacture, use, or commercial sale.

The principal legal issues in this type of action were:

1. Whether Taro's proposed ivermectin cream fell within the asserted composition claims.
2. Whether the proposed formulation satisfied the claimed concentration and excipient limitations.
3. Whether Taro's proposed labeling induced infringement of rosacea-related method-of-use claims.
4. Whether the patent claims were invalid for anticipation, obviousness, lack of written description, or lack of enablement.
5. Whether Galderma could obtain an injunction preventing commercial launch before patent expiration.

The case was therefore a patent-validity and patent-scope dispute, rather than a challenge to ivermectin's general therapeutic activity.

What was the FDA and Orange Book status of Soolantra?

The FDA approved Soolantra Cream, 1%, in December 2014. The product received approval through the drug application process applicable to a new topical dermatology product containing ivermectin.

FDA issue	Analysis
Reference product	Soolantra Cream, 1%
Approval date	December 2014
Regulatory exclusivity	Regulatory exclusivity was separate from the patent term and did not replace patent protection
Orange Book listing	Patent listings covered Soolantra-related intellectual property
Generic pathway	ANDA applicants were required to address listed patents
Paragraph IV effect	Triggered patent litigation and the statutory approval stay

Soolantra was not protected by a new chemical entity patent in the same way as a previously unknown active ingredient. Ivermectin had an established history of systemic use. Galderma's commercial exclusivity depended heavily on formulation, indication, and use patents.

That structure creates a narrower but technically significant patent barrier. A generic company can challenge the listed patents while relying on the established safety and pharmacology of ivermectin.

When did Soolantra lose exclusivity?

Soolantra's regulatory exclusivity and patent exclusivity had different timelines.

Regulatory exclusivity

FDA regulatory exclusivity generally expires independently of Orange Book patents. Because ivermectin was an established active ingredient, the relevant regulatory protection was not equivalent to a five-year new chemical entity period for an entirely new molecule. Any applicable clinical-investigation exclusivity was limited in duration and did not control the long-term commercial window.

Patent exclusivity

The Soolantra patent estate extended beyond the initial FDA exclusivity period. The core patent protection associated with Soolantra was projected to remain relevant into the early 2030s, subject to patent-term adjustment, patent-term extension, the specific patent claims asserted, and any settlement restrictions.

The practical generic entry date depended on:

• The expiration date of each Orange Book-listed patent.
• Whether Taro prevailed on validity or infringement.
• Whether Taro obtained an earlier date under a settlement.
• Whether Galderma listed additional patents after the original litigation.
• Whether Taro could launch under a carved-out label.
• Whether the FDA accepted the proposed formulation as pharmaceutically equivalent.

How did the Paragraph IV challenge affect generic entry?

Taro's Paragraph IV certification allowed it to challenge Galderma's patent rights before marketing its product. Galderma's timely infringement action triggered the statutory 30-month stay of final FDA approval, subject to court action or settlement.

The Paragraph IV framework gave Taro several potential paths:

Patent invalidity

Taro could argue that the claims were obvious in view of prior ivermectin formulations, rosacea treatments, and topical pharmaceutical knowledge. The strongest prior-art arguments would likely concern the selection of ivermectin for rosacea and the use of conventional cream excipients.

Non-infringement

Taro could modify its formulation so it did not meet one or more claim limitations. Differences in emulsifier systems, particle size, preservatives, viscosity, or manufacturing process can be material where the patent claims contain narrow formulation limitations.

Label carve-out

If the asserted claims were directed to a specific method of use, Taro could seek approval with labeling that omitted the patented indication. This route is more difficult where the remaining label or product marketing would still encourage the patented use.

Settlement

A settlement could establish a negotiated launch date before patent expiration. Hatch-Waxman settlements often resolve the litigation without a public merits ruling, leaving the commercial outcome dependent on the confidential or partially disclosed settlement terms.

What was the litigation outcome?

The public record does not establish a reported judicial decision holding the core Soolantra patent invalid or finding Taro's proposed product non-infringing. The case was resolved through the docket process rather than by a published trial judgment that would broadly define the validity of Galderma's ivermectin patent claims.

For commercial analysis, the key point is that the litigation did not eliminate Galderma's Soolantra patent position through a precedential invalidity decision. The absence of a merits ruling reduced the value of the case as a broad patent challenge for other generic applicants.

The litigation also did not establish that every ivermectin 1% cream would infringe. In topical dermatology cases, infringement turns on the exact ANDA formulation, manufacturing process, and proposed label.

Which companies challenged Soolantra's patent estate?

Generic competition for topical ivermectin could arise from several companies with dermatology and topical manufacturing capabilities, including Taro, Perrigo, Teva, Amneal, and other ANDA sponsors. The existence of a Paragraph IV case against one applicant does not establish that all other applicants made the same certification or challenged the same patents.

The competitive risk is shaped by:

Risk factor	Commercial effect
Multiple ANDA applicants	Raises the probability of an earlier generic launch
Narrow formulation claims	Creates design-around opportunities
Method-of-use claims	May permit label carving
Complex topical formulation	Raises development and bioequivalence risk
Limited number of approved suppliers	Can delay scale-up
Patent settlement	May postpone or coordinate entry
FDA product-specific guidance	Can reduce regulatory uncertainty for later applicants

Topical generics face formulation and bioequivalence barriers that do not always apply to conventional oral tablets. The applicant must demonstrate comparable performance even when systemic exposure is low. This can reduce the number of successful challengers and make a patent settlement more valuable to both sides.

How strong was Galderma's Soolantra patent estate?

Galderma's patent estate had moderate-to-strong commercial value because it protected a branded topical formulation in a dermatology market where switching depends on vehicle performance, tolerability, cosmetic acceptability, and physician familiarity.

Strengths

• The product addressed a defined rosacea indication.
• The formulation was commercially differentiated from oral ivermectin.
• Topical bioequivalence can be technically difficult.
• Method-of-use claims could restrict labeling and promotion.
• The patent term extended well beyond the initial FDA approval period.

Weaknesses

• Ivermectin was an old active ingredient.
• Prior art on topical creams and rosacea treatments was extensive.
• A generic could attempt formulation design-around strategies.
• Method-of-use claims may be vulnerable to label carve-outs.
• Multiple generic applicants could create cumulative launch pressure.

The patent estate was stronger as a market-exclusion tool than as a basis for controlling all ivermectin dermatology products. Its value depended on whether competitors could produce an equivalent cream without practicing the asserted claims.

What formulation patents and manufacturing barriers affected entry?

Soolantra's competitive barrier was primarily formulation-based. Important technical variables included the ivermectin concentration, cream vehicle, solubilization or dispersion method, particle characteristics, preservative system, and physical stability.

A generic applicant must manage four separate risks:

1. Patent infringement from matching the protected formulation.
2. Non-equivalence from changing the vehicle.
3. FDA review delays caused by product-specific deficiencies.
4. Commercial underperformance if the generic has inferior spreadability, irritation, absorption, or patient acceptability.

Manufacturing know-how may also matter even where it is not independently patented. Scale-up of a semisolid product can change viscosity, content uniformity, particle distribution, and stability. These risks can limit the number of credible generic entrants.

What revenue exposure did the litigation create for Galderma?

Soolantra's value was tied to Galderma's prescription rosacea franchise and its broader dermatology portfolio. The principal financial exposure was the loss of branded price, not necessarily the loss of all ivermectin demand.

A first generic entrant could cause:

• Rapid price erosion in the reimbursed channel.
• Increased substitution through pharmacy benefit plans.
• Lower branded prescription volume.
• Higher rebate requirements.
• Reduced value of the Soolantra franchise in licensing or acquisition transactions.

The revenue impact would depend on the number of generic entrants and the timing of launch. A single authorized or negotiated entrant can produce a slower erosion curve than simultaneous entry by several ANDA sponsors.

How does Soolantra's patent position compare with conventional oral drugs?

Soolantra had a more formulation-sensitive exclusivity profile than a conventional oral generic.

Factor	Soolantra topical cream	Conventional oral generic
Active ingredient	Established ivermectin	Often established active ingredient
Main patent risk	Formulation and method of use	Compound, salt, polymorph, formulation
Bioequivalence	May require complex topical testing	Usually systemic pharmacokinetic comparison
Design-around potential	Relatively meaningful	Depends on claim structure
Manufacturing risk	High for semisolid scale-up	Often lower after process validation
Label carve-out	Potentially important	Often less commercially decisive

This profile can delay generic entry even after the main active-ingredient exclusivity has ended. It also makes formulation patents and FDA product-specific requirements central to the launch analysis.

Key Takeaways

• Galderma Laboratories sued Taro in D.N.J. case No. 3:16-cv-02207 over Taro's ANDA for generic Soolantra, ivermectin 1% cream.
• The litigation was a Hatch-Waxman Paragraph IV action.
• U.S. Patent No. 9,066,856 was a core patent associated with Soolantra's ivermectin composition and use protection.
• Soolantra's commercial exclusivity depended more on formulation and method-of-use patents than on a new chemical entity patent.
• The public record does not show a reported merits decision invalidating Galderma's principal Soolantra patent rights.
• Generic entry risk depended on settlement terms, Orange Book listings, formulation design-arounds, label carving, and FDA topical-equivalence requirements.
• Galderma's patent estate was commercially meaningful but vulnerable to prior-art, non-infringement, and formulation-design-around challenges.

FAQs

Was Taro's Soolantra challenge a Paragraph IV certification?

Yes. The case was initiated after Taro sought FDA approval for a generic ivermectin 1% cream and challenged Galderma's listed patent rights under the Paragraph IV framework.

Is ivermectin itself patented for rosacea treatment?

The relevant protection was not ownership of ivermectin as a chemical compound. The patent dispute concerned the topical composition and use of ivermectin for rosacea.

Can a generic launch Soolantra with a different cream vehicle?

Potentially. A different vehicle may avoid a formulation claim, but the product must still satisfy FDA requirements for pharmaceutical equivalence or bioequivalence and must avoid infringement of any method-of-use claim.

Does a Soolantra generic need to copy Galderma's rosacea labeling?

Not necessarily. An ANDA applicant may seek a Section viii label carve-out for patented uses, but the remaining label and foreseeable promotion must not induce infringement.

Did the Galderma-Taro case establish that all generic ivermectin creams infringe?

No. Infringement depends on the specific ANDA formulation, manufacturing process, claims, and proposed labeling.

References

1. Food and Drug Administration. (2014). Soolantra (ivermectin) cream, 1%: Prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

3. Galderma Laboratories, L.P. v. Taro Pharmaceuticals U.S.A., Inc., No. 3:16-cv-02207, U.S. District Court for the District of New Jersey.

4. U.S. Patent No. 9,066,856. (2015). Ivermectin compositions and methods of use thereof. U.S. Patent and Trademark Office.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

6. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.